JPMorgan Chase & Co. Acquires 67,557 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

JPMorgan Chase & Co. boosted its holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 20.8% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 391,960 shares of the company’s stock after purchasing an additional 67,557 shares during the quarter. JPMorgan Chase & Co. owned about 0.26% of Xeris Biopharma worth $1,117,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Xeris Biopharma during the 3rd quarter valued at $35,000. Quantbot Technologies LP bought a new stake in Xeris Biopharma in the third quarter valued at $44,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Xeris Biopharma by 64.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 28,657 shares of the company’s stock valued at $82,000 after purchasing an additional 11,239 shares during the period. Goldstein Advisors LLC grew its stake in shares of Xeris Biopharma by 19.7% in the 3rd quarter. Goldstein Advisors LLC now owns 30,425 shares of the company’s stock valued at $87,000 after buying an additional 5,000 shares during the period. Finally, Sanctuary Advisors LLC bought a new stake in Xeris Biopharma in the 2nd quarter valued at about $75,000. 42.75% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on XERS shares. HC Wainwright increased their price target on Xeris Biopharma from $6.00 to $6.60 and gave the stock a “buy” rating in a report on Monday, November 11th. Piper Sandler cut Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 target price on the stock. in a report on Monday, November 11th.

Xeris Biopharma Stock Performance

XERS stock opened at $3.45 on Friday. The business has a 50-day simple moving average of $3.36 and a two-hundred day simple moving average of $2.98. The company has a market capitalization of $514.33 million, a P/E ratio of -7.67 and a beta of 2.62. Xeris Biopharma Holdings, Inc. has a 52-week low of $1.69 and a 52-week high of $3.87.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.